146 results on '"Feng, Joy"'
Search Results
2. Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro
3. Structural basis for substrate selection by the SARS-CoV-2 replicase
4. 539. Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for Obeldesivir
5. Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement
6. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
7. Interfering with nucleotide excision by the coronavirus 3′-to-5′ exoribonuclease
8. Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus
9. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
10. The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2
11. Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir
12. Correction: Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action
13. An atomistic model of the coronavirus replication-transcription complex as a hexamer assembled around nsp15
14. Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells
15. Response to Yan and Muller “Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver”
16. Structural and kinetic insights into binding and incorporation of L-nucleotide analogs by a Y-family DNA polymerase
17. Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
18. Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”
19. Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent
20. Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action
21. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
22. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
23. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
24. Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation
25. Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
26. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study
27. Nucleotide Prodrug Containing a Nonproteinogenic Amino Acid To Improve Oral Delivery of a Hepatitis C Virus Treatment
28. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
29. Addressing the selectivity and toxicity of antiviral nucleosides
30. Off-Target In VitroProfiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent
31. Biochemical characterization of recombinant influenza A polymerase heterotrimer complex: Polymerase activity and mechanisms of action of nucleotide analogs
32. Biochemical characterization of recombinant influenza A polymerase heterotrimer complex: Endonuclease activity and evaluation of inhibitors
33. Broad-spectrum Investigational Agent GS-5734 for the Treatment of Ebola, MERS Coronavirus and Other Pathogenic Viral Infections with High Outbreak Potential
34. Biochemical Characterization of GS-4059 As a Potent and Selective Covalent Irreversible Inhibitor of Bruton's Tyrosine Kinase
35. Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus
36. Nucleotide Prodrug GS-5734 Is a Broad-Spectrum Filovirus Inhibitor That Provides Complete Therapeutic Protection Against the Development of Ebola Virus Disease (EVD) in Infected Non-human Primates
37. Mitochondrial Biogenesis Assay after 5-day Treatment in PC-3 Cells
38. Determination of Mitochondrial DNA Upon Drug Treatment
39. Inhibition of Hepatitis C Virus Replication by GS-6620, a Potent C -Nucleoside Monophosphate Prodrug
40. Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependent Nuclear Transcription to Antiviral Ribonucleosides
41. Structural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir Resistance
42. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study
43. The A62V and S68G Mutations in HIV-1 Reverse Transcriptase Partially Restore the Replication Defect Associated With the K65R Mutation
44. In Vitro Combination of Amdoxovir and the Inosine Monophosphate Dehydrogenase Inhibitors Mycophenolic Acid and Ribavirin Demonstrates Potent Activity against Wild-Type and Drug-Resistant Variants of Human Immunodeficiency Virus Type 1
45. Relationship between Antiviral Activity and Host Toxicity: Comparison of the Incorporation Efficiencies of 2′,3′-Dideoxy-5-Fluoro-3′-Thiacytidine-Triphosphate Analogs by Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Human Mitochondrial DNA Polymerase
46. Characterization of Novel Reverse Transcriptase and Other RNA-associated Catalytic Activities by Human DNA Polymerase γ
47. Dioxolane Guanosine 5′-Triphosphate, an Alternative Substrate Inhibitor of Wild-type and Mutant HIV-1 Reverse Transcriptase
48. Insights into the Molecular Mechanism of Mitochondrial Toxicity by AIDS Drugs
49. Mechanism of Action of 1-β- d -2,6-Diaminopurine Dioxolane, a Prodrug of the Human Immunodeficiency Virus Type 1 Inhibitor 1-β- d -Dioxolane Guanosine
50. Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.